Publishers often slap labels on activities that are complex, expensive, and high-value. Worse, we often accept people calling these activities “value-add” when they are core functions of how scientific information shared.
Authors should not be surprised when their open access articles show up in surprising places. Is it possible to embrace open access with some restrictions?
A lurid story of intramural hijinks at the FDA shows how far from mission an organization can drift when it gets its priorities wrong.
As we continue to measure the number of papers, citations, and the combination, perhaps we should be measuring a much lower number — the number of studies that can be replicated after publication.
Ghostwriters and unnamed contract researchers might scare up controversy, and frighten away the truth. And they’re only part of the problem.